192 related articles for article (PubMed ID: 36464766)
1. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.
Lipe BC; Renaud T
J Oncol Pharm Pract; 2023 Jun; 29(4):1006-1010. PubMed ID: 36464766
[TBL] [Abstract][Full Text] [Related]
2. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
3. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P
Lancet Oncol; 2023 Jun; 24(6):e255-e269. PubMed ID: 37269857
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
Jourdes A; Cellerin E; Touzeau C; Harel S; Denis B; Escure G; Faure E; Jamard S; Danion F; Sonntag C; Ader F; Karlin L; Soueges S; Cazelles C; de La Porte des Vaux C; Frenzel L; Lanternier F; Brousse X; Cazaubiel T; Berger P; Collignon A; Blot M; Pieragostini A; Charles M; Chaleteix C; Redor A; Roland V; Cartau T; Macro M; Chalopin T; Vallet N; Perrot A; Martin-Blondel G;
Clin Microbiol Infect; 2024 Jun; 30(6):764-771. PubMed ID: 38432433
[TBL] [Abstract][Full Text] [Related]
6. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
7. Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
Chari A; Krishnan A; Rasche L; Ye JC; Garfall A; Popat R; Lipe B; Qin X; Campagna M; Masterson T; Tomlinson C; Hilder B; Tolbert J; Renaud T; Smit MD; Gray K; Kane C; Heuck C; van de Donk NWCJ
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38871558
[TBL] [Abstract][Full Text] [Related]
8. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
10. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
11. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
12. Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients.
Valery M; Saleh K; Ecea R; Michot JM; Ribrag V; Fizazi K; Hollebecque A; Lecesne A; Ponce S; Loriot Y; Champiat S; Baldini C; Sarkozy C; Castilla-Llorente C
Cancer Chemother Pharmacol; 2023 Sep; 92(3):229-233. PubMed ID: 37354233
[TBL] [Abstract][Full Text] [Related]
13. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
[TBL] [Abstract][Full Text] [Related]
14. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
[TBL] [Abstract][Full Text] [Related]
15. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
[TBL] [Abstract][Full Text] [Related]
16. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies.
Kauer J; Hörner S; Osburg L; Müller S; Märklin M; Heitmann JS; Zekri L; Rammensee HG; Salih HR; Jung G
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474413
[TBL] [Abstract][Full Text] [Related]
18. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
Chen F; Teachey DT; Pequignot E; Frey N; Porter D; Maude SL; Grupp SA; June CH; Melenhorst JJ; Lacey SF
J Immunol Methods; 2016 Jul; 434():1-8. PubMed ID: 27049586
[TBL] [Abstract][Full Text] [Related]
19. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
Frey NV; Porter DL
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):567-572. PubMed ID: 27913530
[TBL] [Abstract][Full Text] [Related]
20. Managing side effects: guidance for use of immunotherapies in multiple myeloma.
Liang EC; Sidana S
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):348-356. PubMed ID: 38066898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
